SavedAdd your journal

Journals / Endokrinolojide Yönelişler / 2002 / Cilt: 11 - Sayı: 3

The effects of hemodialysis and continuous ambulatory peritoneal dialysis on pklazma total homocysteine concentration

Hemodiyaliz ve sürekli ayaktan periton diyalizi tedavilerinin plazma total homosistein konsantrasyonu üzerine etkisi

Betül KALENDER
Can DUMAN
Berna YALÇIN
Aykut KALKAN
Ahmet YILMAZ
Nilüfer KOÇAK
Pages
127–130
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean plasma tHs concentration was higher in the CAPD patients compared to the control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study our aim was to investigate the effects of HD (Hemodialysis) and CAPD (Continuous ambulatory peritoneal dialysis) treatments on the plasma total homocysteine (tHs) concentrations as an arteriosclerotic risk factor.
📊
Key Findings & Data:B12 concentration serum albumin, urea reduction ratio (URR) and KW in HD and CAPD patients.
💡
Conclusion & Impact:The mean plasma tHs concentration was higher in the CAPD patients compared to the control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study our aim was to investigate the effects of HD (Hemodialysis) and CAPD (Continuous ambulatory peritoneal dialysis) treatments on the plasma total homocysteine (tHs) concentrations as an arteriosclerotic risk factor. In addition it was determined that the relationship between plasma tHs and folic acid, vit. B12 concentration serum albumin, urea reduction ratio (URR) and KW in HD and CAPD patients. Twenty two HD, 18 CAPD .patients (28 male, 12 female) and 24 healthy controls (10 male, 14 female) were enrolled in this study. In HD and CAPD patients mean age was 53.04±15.85, 47.44±15.49 years and mean time on dialysis was 30.00±22.30, 22.61 ±14.10 months respectively. In healthy volunters mean age was 50.91 ±8.71 years. All HD patients were on 1.5 mg/day folate, 10 mg/day vit. B6, 30 meg/day vit. B12. Plasma tHs, serum urea, creatinine, albumin, vit. B12 and folic acid concentrations were measured and URR, KtA/ were calculated in the patients. Plasma tHs were also measured in healthy controls In the HD, the CAPD patients and the healthy controls the mean plasma tHs concentrations were 10.95±4.32 nmol/L, 13.85±8.58 nmol/L and 9.18±2.08 (mol/L respectively. There was no difference between the HD and the CAPD patients and the HD and the healthy controls for plasma tHs concentrations (p>0.05). The mean plasma tHs concentration was higher in the CAPD patients compared to the control group (p

Özet

Bu çalışmada öncelikli amacımız, Hemodiyaliz (HD) ve sürekli ayaktan periton diyalizi (SAPD) tedavilerinin ateroskleroz gelişiminde risk faktörü olan plazma total homosistein (tHs) düzeyi üzerine etkisini araştırmaktır. Ayrıca, plazma tHs ile folik asit, vit. B12, serum albumin, üre azalma oranı (URR), KtA/ arasındaki ilişki değerlendirilecektir. Yirmi ikisi HD, 18'i SAPD tedavisi gören toplam 40 hasta (28 erkek, 12 kadın) ve sağlıklı kontrol grubunu oluşturan 24 kişi (10 erkek, 14 kadın) çalışmaya alındı. HD ve SAPD hastalarının sırasıyla ortalama yaşı 53.04±15.85, 47.44±15.49 yıl ve tedavi süreleri 30.00±22.30, 22.61±14.10 aydı. Kontrol grubunun yaş ortalaması ise 50.91 ±8.71 yıldı. HD hastalarının tamamı günde 1.5 mg folik asit, 10 mg B6, 30 meg B12 vitamini kullanıyordu. Hastalar ve kontrollerde plazma tHs düzeyleri, hastalarda serum üre, kreatinin, albumin, üre azalma oranı (URR), KW, vit. B12 ve folik asit değerleri araştırıldı. HD, SAPD ve sağlıklı kontrol gruplarında ortalama plazma tHs değerleri sırasıyla, 10.95±4.32 n mol/L, 13.85±8.58 (mol/L ve 9.18±2.08 (mol/L bulundu. Plazma tHs değerleri açısından HD ve SAPD grupları ile HD ve sağlıklı kontrol grupları arasında anlamlı farklılık saptanmadı (p>0.05). SAPD hastalarında ise plazma tHs düzeyi sağlıklı kontrol grubundan anlamlı olarak daha yüksek bulundu (p

🔖

Cite This Article

KALENDER, B., DUMAN, C., YALÇIN, B., KALKAN, A., YILMAZ, A., KOÇAK, N. (2022). The effects of hemodialysis and continuous ambulatory peritoneal dialysis on pklazma total homocysteine concentration. Endokrinolojide Yönelişler, Cilt: 11 - Sayı: 3, 127–130. https://ajindex.com/articles/500944

References (13)

  1. Welch GN, Loscalzo T: Homosistein and atherotrombosis. N Engl J Med 338(15): 1042-1050, 1998
  2. Nadir I, Duman N: Kronik böbrek yetmezliği ve hiperhomosisteinemi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 8:46-50, 1999- 3. Chambers JC, Obeid OA, Refsum H et al.: Plasma homocysteine concentrations and risk for coronary heart disease in UK Indian and European men. Lancet 355: 523-527, 2000
  3. Stamler JS, Osborne JA, Jaraki O et al.: Adverse vascular effects of homocysteine are modulated by endotelium derived relaxing factor and related oxidies of nitrogen. J Clin Invest 91: 308-318, 1993
  4. Lentz SR, Sadler JE: Inhibition of trombomodulin surface expression and protein C activation by the trombogenic agent homocysteine. J Clin Invest 88: 1906-1914, 1991
  5. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG: Role of oxidant stress in endotelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 100: Il6l-ll68 1999
  6. Kitiyakara C, Gonin J, Massy Z, Wilcox CS: Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 9: 477-487, 2000
  7. Jungers P, Massy ZA, Khoa TN et al.: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. Nephrol Dial Transplant 12: 2597-2602, 1997
  8. Bostom AG, Lathrop L: Hyperhomocysteinemia in end stage renal disesase: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10-20, 1997
  9. Holdt B, KortenG, Knipppel M et al.: Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int (suppl 1): 246-249, 1996. 11. van Guldener C, Kulik W, Berger R et al.: Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 56:1064-1071,1999
  10. Tamura T, Johnston KE, Bergman SM: Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol 7: 2414-2418, 1996
  11. Arnadottir M, Berg AL, Hegbrant J, Hultberg B: Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 14: 142-146, 1999
  12. Bostom AG, Shemin D, Lapane KL et al.: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123: 193-202, 1996
  13. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazaais JM: The urea reductior ra